Manufacturer record
Rumy Pharmaceuticals: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by Rumy Pharmaceuticals (Himachal Pradesh) were declared Not of Standard Quality between January 2026 and February 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: RPL-1013, Amobroxol Hydrochloride, Guaiphenesin and Levosalbutamol Sulphate Syrup (exp Sep 2027). FDTL,Uttarakhand (state lab) found it not of standard quality: Assay of Levosalbutamol Sulphate IP. Listed in the February 2026 alert.
Records by type
2 records linked to Rumy Pharmaceuticals in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Amobroxol Hydrochloride, Guaiphenesin and Levosalbutamol Sulphate Syrup | Batch RPL-1013Mfg Oct 2025 · Exp Sep 2027 | Assay of Levosalbutamol Sulphate IPAssay | FDTL,UttarakhandState lab | Feb 2026 |
| Ambroxol Hcl, Dextromethorphan Hbr, Phenylephrine Hcl, Chlorpheniramine Maleate & Menthol Syrup | Batch RPL863Mfg May 2025 · Exp Apr 2027 | ContentOther | Drugs Testing Laboratory, Madurai-19State lab | Jan 2026 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.